Copy of Newspaper Publication

Greenply/2026-27 October 30, 2026 The Manager The Manager BSE Limited National Stock Exchange of India Limited Department of Corporate Services Exchange Plaza, Bandra Kurla Complex Floor 25, P. J. Towers, Dalal Street Bandra (E) Mumb-a 4i00 001 Mumb-a 4i00 051 Scrip Code: 526797 Symbol - GREENPLY Dear Sir/ Madam, Sub: Newspaper Publication in respect of un-audited financial results of the Company for the quarter and half year ended 30th September, 2026 Please find enclosed herewith the copies of newspaper Publication in respect of un-audited financial results of the Company for the quarter and half year ended on 30th September, 2026, as published in Business Standard, all editions (English Language) and Aajkal, (Bengali Language) on 30.10.2026. This above is for your information and record. Thanking You, Yours faithfully, For GREENPLY INDUSTRIES LIMITED KAUSHAL KUMAR AGARWAL COMPANY SECRETARY & VICE PRESIDENT-LEGAL Greenply Industries Limited ‘Madgul Lounge’, 5th & 6th Floor, 23 Chetla Central Road, Kolkata - 700027, West Bengal, India T:+91 33 24500400, 30515000 | E: kaushal.agarwal@greenply.com | www.greenply.cam | CIN: L20211WB1990PLC268743 Registered Office :'Madgul Lounge’, 6th Floor, 23 Chetla Central Road, Chetla, Kolkata - 700027, West Bengal, India 10 TECHNOLOGY KOLKATA | FRIDAY, 30 OCTOBER 2026 Business Standard Pharma and healthcare EUROPE GIVES FILLIP DESPITE US FALL Pharma exports grow 5% in first half of FY27 deals surge 23% in Q3 India’s pharmaceutical and corded this quarter, private deals healthcare sector recorded 87 such as mergers and acquisitions SANKET KOUL Exports to Europe increased DRUG FORMULATIONS AND BIOLOGICALS The geographical gains were plied by Indian pharmaceutical transactions valued at $4.3 bil- (M&A) and private equity (PE) New Delhi, 29 October 9.66 per cent to $3.29 billion, ac- REMAINED THE LARGEST EXPORT CATEGORY, matched by growth in Key prod- exporters,” Pharmexcil said. lion in the third quarter of activity accounted for around counting for over one-fifth of ACCOUNTING FOR 73.84% OF TOTAL SHIPMENTS, uct categories over the same Pharmexcil Chairman 2026 (July to September $2.3 billion across 81 transac- Pharmaceutical exports grew total pharmaceutical exports in WITH ITS SHARE GROWING BY 3.81% period. Drug formulations and Namit Joshi added that the next period), according to a report tions. While M&A activity in the 4.9 per cent year-on-year (Y-o- HI1FY27, with Germany, the Ne- biologicals remained the largest phase of India’s pharma export by Grant Thornton Bharat. healthcare and pharmaceutical Y) to $16.14 billion during the therlands and France recording export category, accounting for growth should focus on moving This is a 23 per cent rise in sector saw a marginal 6 per cent first half of 2026-27 (H1FY27), on strong growth. 73.84 per cent of total ship- up the value chain, where In- volumes and a 69 per cent drop rise in volumes compared with higher dealings with non- “The gains across these ments, with its share growing by dian companies are not just in values compared to Q2 2025 the previous quarter, the PE United States (US) markets, markets highlight the oppor- 3.81 per cent over the previous suppliers but active partners in (April to July), which saw 65 de- landscape recorded a 69 percent even asshipmentstotheUS fell. tunities for Indian exporters to corresponding period. “Bulk pharmaceutical innovation. alsin the sector worth $13.9 mil- rise in volumes. While the Pharmaceutical deepen their engagement with drugs and drug intermediates “This will require greater in- lion. The drop in deal value was Public market fundraising Export Promotion Council of Europe,” Pharmexcil stated. America and the Caribbean re- ort growth, even as shipments to grew 12.07 per cent, while surgi- vestment in research and devel- attributable to the $11.75 billion also strengthened, with four India (Pharmexcil) did not Similarly, shipments to the corded 16.58 per cent growth the US moderated, highlighting cal exports increased 9.53 per opment, technology transfer Sun Pharma- Organon transact- Initial Public Offerings raising share data for US markets, it Association of South East and Africa grew 6.48 per cent. the importance of a geograph- cent. The product mix under- and co-development of com- ion in Q2 2026, rather than aslo- $1.27 billion and two qualified claimed that export shipments Asian Nations (ASEAN) grew “These gains also helped sus- ically diversified export pres- scores the range of medicines plex generics, biosimilars and wdown in underlying activity. institutional placements rai- moderated during the period. 21.54 per cent, while Latin tain India’s overall pharma exp- ence,” Pharmexcil stated. and healthcare products sup- specialised therapies,” he said. Of the $4.3 billion in deals re- sing $162 million. SANKET KOUL Govt, Volkswagen clash GREENPLY INDUSTRIES LIMITED in court over record $1.2 billion tax dispute Registered Office: “Madgul Lounge”, 6th Floor, 23 Chetla Central Road, Kolkata - 700 027 Corporate Identification Number: L20211WB1990PLC268743 REUTERS Industries Limited Phone: (033) 3051-5000, E-mail: Investors@greenply.com, Website: www.greenply.com 29 October India defended its record $1.2 UN-AUDITED FINANCIAL RESULTS FOR THE billion tax demand against Volkswagen (VW) in a Mum- bai court on Thursday, saying QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026 the German company never provided required informa- tion in time, while the car- maker argued the demand The Board of Directors of Greenply Industries Limited (“the Company”) at its meeting held on October came years too late. THE CASE WILL NEXT BE India has since 2024 al- HEARD ON TUESDAY 29, 2026 has approved the un-audited standalone and consolidated financial results for the quarter leged Volkswagen under- valued auto imports for years and half year ended September 30, 2026, in terms of Regulation 33 of SEBI (Listing Obligations and and paid below the full tariff law allows officials to only go rates. The case is a major over- back up to the past five years. Disclosure Requirements) Regulations, 2015. hang for the carmaker, which Additional Solicitor Gen- is currently in talks with eral N Venkataraman, one of The aforementioned financial results along with the limited review reports of the Statutory Auditors India’s JSW to sella stake in its the government's top lawyers, India operations. said Volkswagen didn’t pro- have been posted on the Company’s website at https://www.greenply.com/investors and can be Volkswagen, which has a vide the information sought in roughly 2 per cent market time, adding that no other accessed by scanning the QR code. share in the world’s third big- automaker in the country gest car market, denies the which imports parts had in- allegations, and has pre- dulged in such misconduct. viously said the case is a “No other company has By Order of the Board matter of “life and death” for challenged this,” he said. its India business, and is “im- Volkswagen is accused of For GREENPLY INDUSTRIES LIMITED possibly enormous”. declaring its imports as indi- The dispute over India’s vidual auto parts and paid 5 per Sd/- biggest ever import tax de- cent to 15 per cent tariff, though mand restarted last week itwas bringingin “almost the Sanidhya Mittal after the high court in Mum- entire car” in unassembled bai said in August it would condition for which it should Date : October 29, 2026 Joint Managing Director hear Volkswagen challenge have paid a 30-35 per cent tax Place : Kolkata [DIN : 06579890] afresh as judges failed to pass rate, India has alleged. aruling in time. The probe has spooked for- On Thursday, Volk- eign investors, as lengthy im- swagen’s counsel Arvind port tariff and tax cases have Note: The above intimation is in accordance with Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligations Datar told the judges India long been a sore point for com- <a. tax authorities could not have panies and aff [Showing first 8,000 characters — download PDF for full document]